SYGNIS AG successfully completes Rights Offering and Private Placement


SYGNIS AG / Key word(s): Capital Increase

10.12.2015 19:30

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement according to § 15 WpHG

---------------------------------------------------------------------------

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN
AND AUSTRALIA

SYGNIS AG successfully completes Rights Offering
and Private Placement

- Rights offering and private placement raise EUR 5.6 million

- Gross proceeds secure funds for working capital needs

- Major shareholder Genetrix S.L., Spain, contributes EUR 0.6 million in
kind by swapping its shareholder loan into equity

Madrid, Spain and Heidelberg, Germany, December 10, 2015 - SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that
the Company has successfully completed its rights offering and the
subsequent private placement. A total number of 2,962,552 shares were
placed at a subscription price of EUR 1.90 per share.

In a cash capital increase 2,962,552 offered shares were placed with
existing shareholders in a rights issue and with selected new institutional
investors in a subsequent rump placement, which resulted in gross proceeds
of more than EUR 5.6 million.

Furthermore, a total of 315,789 consideration shares will be issued at the
same issue price of EUR 1.90 by way of a capital increase against
contributions in kind in order to swap the shareholder loan from the main
shareholder Genetrix S.L., Spain, of approximately EUR 0.6 million into
equity. Thus, the capital increase amounted to EUR 6.2 Mio. in total.

By completion of this transaction, including the contribution in kind, the
Company's share capital will increase from EUR 13,494,934.00 composed of
13,494,934 no-par value bearer shares, to EUR 16,773,275.00 composed of
16,773,275 shares, by issuing 3,278,341 new shares while partially
utilising authorized capital. The new shares carry full dividend rights as
of January 1, 2015.

SYGNIS plans to use the gross proceeds of EUR 5.6 million to finance the
expansion of its commercialization activities and customer base worldwide,
especially to the US, to further progress its product portfolio and also
includes the repayment of soft loans.

**** End of ad hoc announcement ****



For further information please contact:

SYGNIS AG MC Services AG
Pilar de la Huerta Raimund Gabriel
CEO/CFO Managing Partner
Phone: +34 91 192 36 50 Phone: +49 89 210228 30
Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu



About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes on the development
and commercialization of innovative products for DNA amplification and
sequencing. Based on its proprietary technologies, SYGNIS has developed a
commercial product portfolio addressing key challenges in the fast growing
fields of molecular biology and next generation sequencing applications.
Key products include the TruePrime(TM) product line and SensiPhi(R),
licensed to an industry leading partner, for whole genome DNA amplification
and sequencing as well as the SunScript(TM) Reverse Transcriptase product
family to convert genetic information from RNA molecules back to DNA.
SYGNIS AG is listed at the German Stock Exchange in the Prime Standard
segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This document is not a securities prospectus and the information
contained therein does not constitute an offer to sell or a solicitation of
an offer to purchase any securities of SYGNIS AG in Federal Republic of
Germany nor under any other jurisdiction, in particular not where such kind
of offer or solicitation is prohibited or lacks the required permission.
Potential investors in securities of SYGNIS AG are asked to familiarize
themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on
the basis of the securities prospectus detailing the public offering of
securities of SYGNIS AG in the Federal Republic of Germany, which is
published on www.sygnis.com in the section "investors".

The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to US
Persons (as defined in regulation S of the US Securities Act of 1933) or to
publications with a general circulation in the United States with the
exception of a such disclosures or announcements outside the Federal
Republic of Germany which have to be made under the respective mandatory
law. Any person who fails to comply with these restrictions may violate the
security laws of certain jurisdictions, in particular of the United States.
Securities in SYGNIS AG are not publicly offered outside the Federal
Republic of Germany. ###


10.12.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------